Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Disturbance in attention? 157 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 157 reports of Disturbance in attention have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.1% of all adverse event reports for TOFACITINIB.

157
Reports of Disturbance in attention with TOFACITINIB
0.1%
of all TOFACITINIB reports
0
Deaths
18
Hospitalizations

How Dangerous Is Disturbance in attention From TOFACITINIB?

Of the 157 reports, 18 (11.5%) required hospitalization, and 1 (0.6%) were considered life-threatening.

Is Disturbance in attention Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 157 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Disturbance in attention?

LEVOTHYROXINE (1,718) METHYLPHENIDATE (1,414) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (1,321) DULOXETINE (986) PREGABALIN (950) LISDEXAMFETAMINE DIMESYLATE (911) OXYCODONE (829) QUETIAPINE (747) ACETAMINOPHEN\HYDROCODONE (746) ACETAMINOPHEN\OXYCODONE (734)

Which TOFACITINIB Alternatives Have Lower Disturbance in attention Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Disturbance in attention Reports All Drugs Causing Disturbance in attention TOFACITINIB Demographics